Barclays Initiates Coverage on Omada Health (NASDAQ:OMDA)

Barclays initiated coverage on shares of Omada Health (NASDAQ:OMDA - Get Free Report) in a research report issued on Tuesday, MarketBeat reports. The firm set an "overweight" rating and a $21.00 price target on the stock. Barclays's price objective would suggest a potential upside of 12.72% from the company's current price.

Other analysts also recently issued research reports about the stock. The Goldman Sachs Group began coverage on shares of Omada Health in a report on Tuesday. They issued a "buy" rating and a $29.00 price target on the stock. Wall Street Zen raised Omada Health to a "hold" rating in a research note on Monday, June 16th. Needham & Company LLC assumed coverage on Omada Health in a research report on Tuesday. They set a "buy" rating and a $23.00 price target for the company. Finally, Canaccord Genuity Group started coverage on Omada Health in a research report on Tuesday. They issued a "buy" rating and a $27.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $23.57.

Omada Health Price Performance

Omada Health stock traded up $0.53 during trading hours on Tuesday, hitting $18.63. The stock had a trading volume of 344,526 shares, compared to its average volume of 1,585,299. Omada Health has a 1-year low of $14.14 and a 1-year high of $28.40.

Omada Health Company Profile

Omada's mission is to bend the curve. Our hope is that, one day, tomorrow's epidemiologists will notice a bend in disease curves, wonder what might be happening, and conclude that part of that impact has been Omada. As part of that mission, we strive to inspire and enable people to make lasting health changes on their own terms.